The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression
Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we e...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/212893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564582541950976 |
|---|---|
| author | Cristoforo Comi Giuseppe Cappellano Annalisa Chiocchetti Elisabetta Orilieri Sara Buttini Laura Ghezzi Daniela Galimberti Franca Guerini Nadia Barizzone Franco Perla Maurizio Leone Sandra D’Alfonso Domenico Caputo Elio Scarpini Roberto Cantello Umberto Dianzani |
| author_facet | Cristoforo Comi Giuseppe Cappellano Annalisa Chiocchetti Elisabetta Orilieri Sara Buttini Laura Ghezzi Daniela Galimberti Franca Guerini Nadia Barizzone Franco Perla Maurizio Leone Sandra D’Alfonso Domenico Caputo Elio Scarpini Roberto Cantello Umberto Dianzani |
| author_sort | Cristoforo Comi |
| collection | DOAJ |
| description | Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the -156G>GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the +1239A>C SNP. We found that only +1239A>C SNP displayed a statistically significant association with MS development, but both +1239A>C and -156G>GG had an influence on MS progression, since patients homozygous for both +1239A and −156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or −156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses. |
| format | Article |
| id | doaj-art-fcd5b8a62ae742f7932a6f9ad6c3e5ff |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-fcd5b8a62ae742f7932a6f9ad6c3e5ff2025-02-03T01:10:43ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/212893212893The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and ProgressionCristoforo Comi0Giuseppe Cappellano1Annalisa Chiocchetti2Elisabetta Orilieri3Sara Buttini4Laura Ghezzi5Daniela Galimberti6Franca Guerini7Nadia Barizzone8Franco Perla9Maurizio Leone10Sandra D’Alfonso11Domenico Caputo12Elio Scarpini13Roberto Cantello14Umberto Dianzani15Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyDino Ferrari Center, The University of Milan, Fondazione Cà Granda, IRCCS Ospedale Haggior Policlinico, Milan, ItalyDino Ferrari Center, The University of Milan, Fondazione Cà Granda, IRCCS Ospedale Haggior Policlinico, Milan, ItalyMultiple Sclerosis Unit, Don C Gnocchi Foundation, IRCCS, S Maria Nascente, Milan, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyDepartment of Neurology, Mondovì Hospital, Mondovì, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyMultiple Sclerosis Unit, Don C Gnocchi Foundation, IRCCS, S Maria Nascente, Milan, ItalyDino Ferrari Center, The University of Milan, Fondazione Cà Granda, IRCCS Ospedale Haggior Policlinico, Milan, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyInterdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, “Amedeo Avogadro”, Novara, ItalyOsteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the -156G>GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the +1239A>C SNP. We found that only +1239A>C SNP displayed a statistically significant association with MS development, but both +1239A>C and -156G>GG had an influence on MS progression, since patients homozygous for both +1239A and −156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or −156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses.http://dx.doi.org/10.1155/2012/212893 |
| spellingShingle | Cristoforo Comi Giuseppe Cappellano Annalisa Chiocchetti Elisabetta Orilieri Sara Buttini Laura Ghezzi Daniela Galimberti Franca Guerini Nadia Barizzone Franco Perla Maurizio Leone Sandra D’Alfonso Domenico Caputo Elio Scarpini Roberto Cantello Umberto Dianzani The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression Clinical and Developmental Immunology |
| title | The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression |
| title_full | The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression |
| title_fullStr | The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression |
| title_full_unstemmed | The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression |
| title_short | The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression |
| title_sort | impact of osteopontin gene variations on multiple sclerosis development and progression |
| url | http://dx.doi.org/10.1155/2012/212893 |
| work_keys_str_mv | AT cristoforocomi theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT giuseppecappellano theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT annalisachiocchetti theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT elisabettaorilieri theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT sarabuttini theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT lauraghezzi theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT danielagalimberti theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT francaguerini theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT nadiabarizzone theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT francoperla theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT maurizioleone theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT sandradalfonso theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT domenicocaputo theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT elioscarpini theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT robertocantello theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT umbertodianzani theimpactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT cristoforocomi impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT giuseppecappellano impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT annalisachiocchetti impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT elisabettaorilieri impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT sarabuttini impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT lauraghezzi impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT danielagalimberti impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT francaguerini impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT nadiabarizzone impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT francoperla impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT maurizioleone impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT sandradalfonso impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT domenicocaputo impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT elioscarpini impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT robertocantello impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression AT umbertodianzani impactofosteopontingenevariationsonmultiplesclerosisdevelopmentandprogression |